← Back to headlines
Celularity Finalizes Strategic License Deal for Biomaterials Portfolio
Celularity has successfully secured a strategic license deal for its biomaterials portfolio, with the agreement potentially valued at up to $35 million.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
Related Stories
Fed Chair Warsh Signals Potential Rate Hikes Amid Persistent Inflation at Jackson Hole
14m ago
Fed Official Warsh Warns US Inflation Remains Concerning, Pledges 2% Target
36m ago
Walmart Reaches Settlement With US Government Over Opioid Lawsuit
37m ago
Fed Chair Warsh Warns Persistent Inflation Requires Continued Policy Action
1h ago